证券日报网讯 12月15日晚间，锦好医疗发布公告称，公司第三届董事会第十八次会议审议通过《关于 公司续聘会计师事务所的议案》等多项议案。 （文章来源：证券日报） ...

来源：市场资讯 1、关于公司续聘会计师事务所的议案 2、关于预计2026年向银行申请综合授信额度的议案。 锦好医疗发布公告，将于2025年12月31日召开第4次临时股东大会，网络投票日为12月30日。股权登记 日为12月25日，当日收市后持有锦好医疗股票的投资者可以参与投票。 会议地点：惠州市仲恺高新区四环南路(惠环段)207号锦好智慧医疗产业园1楼会议室。 本次股东大会共计审议2项议案，具体如下： ...

证券日报网讯12月12日晚间，锦好医疗发布公告称，股东锦同盛拟自公告披露之日起15个交易日后的3 个月内，通过集中竞价或大宗交易方式减持不超过50万股，占公司总股本0.5078%，减持股份来源于北 交所上市前取得，原因为经营发展需要。 ...

Core Viewpoint - JinHao Medical is a leading enterprise in the hearing health sector, achieving rapid growth through continuous technological innovation, global market expansion, and a commitment to deep industry engagement, aiming to become the world's top hearing aid brand and provide better hearing solutions for the hearing impaired globally [1]. Technological Foundation - The hearing aid industry is interdisciplinary, integrating audiology, acoustics, electronics, and psychology. JinHao Medical has significantly increased R&D investment, achieving breakthroughs in chip design, algorithm development, and product miniaturization, including low-power digital hearing aid chips and AI speech enhancement algorithms [3][4]. - The company has a clear path to catch up with international giants, focusing on enhancing its algorithm development depth and clinical trial richness, with a strategy of "ALL in AI" to leverage AI for rapid advancement in the Chinese hearing aid industry [3][4]. Global Market Expansion - The aging population and increased health awareness are driving the hearing aid market's growth in China, with the market size increasing from 2.84 billion to 5.51 billion CNY from 2015 to 2019, reflecting a CAGR of 18.02%. JinHao Medical aims to expand its market share through a comprehensive market expansion strategy [7]. - The company has established online stores on platforms like JD.com and Tmall, and is building a retail network combining direct sales and distribution. Internationally, it has gained certifications from the FDA and EU, allowing entry into major retail chains [7][8]. Product and Brand Strategy - JinHao Medical is focusing on product differentiation across various price segments, leveraging its technological advantages to create a competitive edge for its own brand while avoiding direct competition with ODM clients [8]. - The company is enhancing its brand image by ensuring product quality and implementing a dual-brand strategy targeting both over-the-counter and professional medical-grade products for different levels of hearing loss [10]. Future Development and Integration - JinHao Medical plans to extend its business along the hearing aid industry chain through both organic growth and acquisitions, aiming to integrate upstream components like chips and algorithms, and downstream retail channels to enhance its industry influence and competitiveness [11].

近日，由中国证券报联合北京证券交易所开展的2025北交所万里行调研活动走进锦好医疗。作为听力健 康领域的领军企业，锦好医疗凭借持续的技术创新、全球化的市场布局和坚定的产业深耕，实现了经营 业绩的快速增长，更在打破海外垄断的道路上稳步前行。 锦好医疗董事长王敏在接受中国证券报记者专访时介绍，从自研芯片突破到AI技术赋能，从跨境渠道 拓展到国内市场深耕，锦好医疗以"做全球最放心的医疗器械"为使命，正朝着"成为助听器行业世界第 一品牌"的愿景迈进，力争为全球听障者带来更优质的听力解决方案。 技术攻坚筑根基 助听器虽体积小巧，却是一个集合了听力学、声学、电子学、心理医学的跨学科产业，集成了多项高科 技零部件与前沿技术。锦好医疗深谙核心技术的重要性，多年来持续加大研发投入，在芯片设计、算法 研发、产品小型化等关键领域不断取得突破，成功研发并量产应用低功耗数字助听器芯片，开发出具有 AI言语增强功能的算法，以及自主测听、自主验配软件，让助听器在性能提升的同时，更贴合用户实 际使用需求。 面对目前与国际巨头的差距，锦好医疗制定了清晰的追赶路径。目前，企业在助听器算法研发深度、第 一代集成电路芯片模数转换、ADC模块声音采集 ...

Core Viewpoint - JinHao Medical is positioned as a leading enterprise in the hearing health sector, focusing on technological innovation and global market expansion to achieve rapid growth and break overseas monopolies [1] Group 1: Technological Advancements - The company emphasizes the importance of core technology and has increased R&D investment, achieving breakthroughs in chip design, algorithm development, and product miniaturization [2] - JinHao Medical is concentrating on AI hearing aid algorithms to enhance user experience, improving speech enhancement in noisy environments and enabling smart fitting and adjustment through apps and remote services [3] - The company has developed several core technologies in self-researched chips, including low-power audio signal conversion and noise enhancement algorithms, and is optimizing the next generation of AI hearing aid chips [4] Group 2: Market Expansion - The hearing aid market in China has shown significant growth, with a CAGR of 18.02% from 2015 to 2019, and JinHao Medical aims to expand its market share through a comprehensive market strategy [5] - The company has established online stores on platforms like JD and Tmall, and is building a retail network combining direct sales and distribution [5] - JinHao Medical is leveraging global certifications to enter international markets, including partnerships with major retailers in the U.S. and establishing subsidiaries in Southeast Asia [5] Group 3: Brand Development - JinHao Medical has made significant strides in developing its own brand, focusing on product differentiation and a full-channel strategy to achieve simultaneous domestic and international market growth [6] - The company is enhancing its brand image by controlling product quality and establishing a differentiated brand identity, targeting both OTC and professional medical-grade products [7] - The company is committed to building a robust talent system to support long-term development, focusing on attracting skilled professionals to enhance R&D and product innovation [7] Group 4: Future Strategy - JinHao Medical plans to extend its business along the hearing aid industry chain through internal growth and external acquisitions, aiming to integrate upstream and downstream resources [8] - The company will focus on acquiring core components and technologies related to hearing aids, as well as retail channels and established brands, to enhance its industry influence and competitiveness [8]

● 本报记者 万宇 近日，由中国证券报联合北京证券交易所开展的2025北交所万里行调研活动走进锦好医疗。作为听力健 康领域的领军企业，锦好医疗凭借持续的技术创新、全球化的市场布局和坚定的产业深耕，实现了经营 业绩的快速增长，更在打破海外垄断的道路上稳步前行。锦好医疗董事长王敏在接受中国证券报记者专 访时介绍，从自研芯片突破到AI技术赋能，从跨境渠道拓展到国内市场深耕，锦好医疗以"做全球最放 心的医疗器械"为使命，正朝着"成为助听器行业世界第一品牌"的愿景迈进，力争为全球听障者带来更 优质的听力解决方案。 技术攻坚筑根基 助听器虽体积小巧，却是一个集合了听力学、声学、电子学、心理医学的跨学科产业，集成了多项高科 技零部件与前沿技术。锦好医疗深谙核心技术的重要性，多年来持续加大研发投入，在芯片设计、算法 研发、产品小型化等关键领域不断取得突破，成功研发并量产应用低功耗数字助听器芯片，开发出具有 AI言语增强功能的算法，以及自主测听、自主验配软件，让助听器在性能提升的同时，更贴合用户实 际使用需求。 面对目前与国际巨头的差距，锦好医疗制定了清晰的追赶路径。目前，企业在助听器算法研发深度、第 一代集成电路芯片模数转换 ...

截至2025年11月25日收盘，锦好医疗（920925）报收于31.13元，较前一交易日上涨0.81%，最新总市值 为30.65亿元。该股当日开盘31.03元，最高31.88元，最低30.81元，成交额达2010.52万元，换手率为 1.16%。 公司近日发布公告称，惠州市锦好医疗科技股份有限公司于2025年11月20日召开2025年第三次临时股东 会，会议审议通过《关于使用部分闲置自有资金购买银行理财产品的议案》。出席本次股东会的股东共 5人，代表有表决权股份总数的61.0135%，表决结果为同意股数占比100%，无反对和弃权情况。广东东 方昆仑（东莞）律师事务所对本次会议进行了见证，并出具法律意见书，认为本次股东会的召集、召开 程序合法合规，决议合法有效。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《2025年第三次临时股东会决议公告》 《广东东方昆仑(东莞)律师事务所关于惠州市锦好医疗科技股份有限公司2025年第三次临时股东 会法律意见书》 ...

Core Insights - The company JinHao Medical (920925) saw a stock price increase of 3.33%, closing at 35.70 CNY per share on November 4 [1] - The company specializes in the research, production, and sales of rehabilitation and home medical devices, including hearing aids, nebulizers, and anti-decubitus air cushions [1] - China is the second-largest rehabilitation medical device market globally, projected to capture 25% of the global market share by 2025, with significant growth potential due to low per capita device ownership compared to developed countries [1] Industry Overview - The rehabilitation and home medical device market is experiencing explosive growth driven by aging populations, technological advancements, and supportive policies, with three key segments: smart rehabilitation devices, home health monitoring systems, and health data services [2] - The market size for home health monitoring devices alone is expected to reach 60 billion CNY by 2025, with wearable devices accounting for over 60% of this segment [2] - The combined market size for core home-related segments is projected to reach 170 billion CNY, with annual growth rates generally exceeding 20% [2] - The rehabilitation medical device and home medical device sectors are in a rapid expansion phase, benefiting from multiple factors including accelerated aging, high prevalence of chronic diseases, increased health awareness, policy support, and technological innovation [2] Company Performance - JinHao Medical reported a revenue of 195.7 million CNY for the third quarter of 2025, representing a year-on-year increase of 82.44%, while net profit reached 17.63 million CNY, up 565.54% year-on-year [2]

证券研究报告·公司点评报告 2025 年 11 月 3 日 江海证券研究发展部 医药行业研究组 执业证书编号：S1410524050001 | | | | 市场数据 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 总股本(百万股) | | 98.46 | | | | | | | | A 股股本(百万股) | | 98.46 | | | | | | | | B/H 股股本(百万股) | | | | | | -/- | | | | A 股流通比例(%) | | 56.16 | | | | | | | | 12 个月最高/最低(元) | | 40.48/10.53 | | | | | | | | 第一大股东 | | | | | | | | 王敏 | | 第一大股东持股比例(%) | | 25.81 | | | | | | | | 上证综指/沪深 300 | | | | | | | 3954.79/4640.67 | | | 数据来源：聚源 注：2025 | 月 | 日数据 | 年 | 10 | 31 | | | ...